Startup profile · funding coverage
Geneoscopy funding, valuation and investors
GI diagnostics company — noninvasive colorectal cancer screening (ColoSense) and related tests.
Keep track of Geneoscopy
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series C
$105M · January 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$105M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · St. Louis, MO
Investors in latest funding
Lead: Bio-Rad Laboratories
Other: Petrichor , Labcorp , Morningside Ventures , Lightchain Capital
Overview
Geneoscopy develops diagnostic tests for gastrointestinal health. Its lead product ColoSense is a noninvasive, stool-based colorectal cancer screening test using RNA biomarkers (with Bio-Rad Droplet Digital PCR technology cited in coverage). In January 2025 the St. Louis company closed a $105 million Series C led by Bio-Rad Laboratories, with Petrichor, Labcorp, Morningside Ventures, Lightchain Capital, NT Investments, Granger Management/Mercy Health, Tri Locum Partners, and others. Proceeds support ColoSense commercialization and pipeline work including IBD-related diagnostics.
Why Geneoscopy is interesting
St. Louis GI diagnostics company that closed a $105M Series C (Jan 2025) led by Bio-Rad to commercialize ColoSense — RNA stool biomarker CRC screening with Labcorp distribution partnership.
Product & use cases
Stool-based molecular diagnostics for colorectal cancer screening and broader GI disease detection.
- At-home CRC screening programs
- Health-system screening pathways with Labcorp ordering
- Future IBD diagnostic expansion
Key facts
- Series C (Jan 2025): $105M led by Bio-Rad Laboratories (company / GenomeWeb)
- Participants included Labcorp, Petrichor, Morningside Ventures, and others
- Lead product: ColoSense noninvasive CRC screening
- St. Louis, MO HQ
Funding history (newest first)
Series C
2025-01 $105M- Bio-Rad Laboratories (lead)
- Petrichor (participant)
- Labcorp (participant)
- Morningside Ventures (participant)
- Lightchain Capital (participant)
Source: Read source · geneoscopy.com
Competitive landscape
Edge: RNA biomarker CRC test with strategic capital and distribution from Bio-Rad and Labcorp.
-
Exact Sciences (Cologuard) direct
Market-leading stool DNA CRC screening.
-
Guardant / blood-based CRC tests adjacent
Blood-based screening alternatives.
-
Colonoscopy providers incumbent
Gold-standard procedural screening.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Geneoscopy's financing or category context.
FAQs about Geneoscopy
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.